Yi-Chiao Li

Yi-Chiao Li

Auto-generated profile, based on publicly available information

Yi-Chiao Li

Save Sight Institute, University of Sydney Medical School, Sydney, New South Wales, Australia

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in Plant Science
Verified
Journal Article
Closed access
RDRevel SM Drummond
Revel SM Drummond
ATA. Tutone
A. Tutone
YLY.-C. Li
Y.-C. Li
RGR.C. Gardner
R.C. Gardner

5 August 2010 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
YLYi‐Chiao Li
Yi‐Chiao Li
EMEmma McCahon
Emma McCahon
NRNeil A Rowe
Neil A Rowe
PMPeter A Martin
Peter A Martin
GWGeoffrey A Wilcsek
Geoffrey A Wilcsek
FMFrank J Martin
Frank J Martin

1 February 2003 in Journal of Hematotherapy & Stem Cell Research
Verified
Journal Article
Closed access
AFAaron E. Foster
Aaron E. Foster
DGDavid J. Gottlieb
David J. Gottlieb
MMMarina Marangolo
Marina Marangolo
ABAnna Bartlett
Anna Bartlett
YLYi-Chiao Li
Yi-Chiao Li
KBKenneth F. Bradstock
Kenneth F. Bradstock
Adoptive transfer of donor-derived cytomegalovirus (CMV)-specific cytotoxic T cell (CTL) clones can restore immunity in allogeneic stem cell transplant recipients, providing protection against CMV disease. Current methods for selecting and expanding CMV-specific T cell clones are technically difficult, making adoptive T cell therapy impractical for routine clinical use. In this study, we describe a method for ex vivo generation and expansion of high-purity CMV-specific CTL using peptide-pulsed dendritic cells as antigen-presenting cells. Generation of CMV-specific CTL in numbers sufficient for clinical use in the time span of 4 weeks was accomplished in 6 of 8 CMV-seropositive donors. Examination of pp65 specificity by HLA/peptide tetramer staining demonstrated that a purity of greater than 95% peptide-specific cells could be obtained after two weekly stimulations and retained after further expansion for 3-4 weeks. Median expansion of total cell number was greater than 500-fold and expansion of peptide-specific CTL by tetramer staining was greater than 1.7 × 105-fold. Four weeks after initiating CTL culture, we were able to generate greater than 109 total cells that specifically lysed target cells loaded with CMV peptide and cells infected with CMV. This simple and rapid method for generating high-purity CMV-specific CTL for adoptive immunotherapy is currently being examined for routine clinical use for allogeneic stem cell transplantation.

7 August 2006 in Medical Journal of Australia
Verified
Journal Article
Closed access
PDF file
YLYi‐Chiao Li
Yi‐Chiao Li
AZAlina Zeldovich
Alina Zeldovich
BCBrian J Chua
Brian J Chua
NRNeil J Rowe
Neil J Rowe
FMFrank J Martin
Frank J Martin
KMKathleen A McClellan
Kathleen A McClellan
Click on the article title to read more.

1 April 2004 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
AFAaron E. Foster
Aaron E. Foster
KFKurt Forrester
Kurt Forrester
YLYi-Chiao Li
Yi-Chiao Li
DGDavid J. Gottlie
David J. Gottlie
Harnessing the power of the immune system to eliminate infection and cancer is a long-standing goal in clinical immunology. The development of a robust immune response to foreign antigen relies, in part, on communication between cellular components of the immune system. The proteins involved in governing the magnitude and longevity of an immune response are collectively called cytokines. Cytokines act directly on immune cells to induce proliferation, differentiation and tolerance, and signaling errors can lead to autoimmune disease or immune deficiency. Identification of the molecules involved in these signaling processes has allowed investigators to manipulate immune cells for therapeutic effect, both in vivo and ex vivo. While in vivo immune modulation using cytokines has produced some exciting results, the toxicity involved with systemic administration has limited their broad use in the clinic. Therefore, research has been focused on the ex vivo manipulation of immune cells for adoptive transfer to treat cancer and infection. This review will focus on the ex vivo manipulation of immune cells with particular emphasis on stimulating cytotoxic T cell responses. Adoptive transfer of ex vivo generated cell types may then be used to treat malignant and viral disease.

4 July 2006 in British Journal of Cancer
Verified
Journal Article
Open access
DGD J Gottlieb
D J Gottlieb
YLY-C Li
Y-C Li
ILI Lionello
I Lionello
STS Tanzarella
S Tanzarella
MMM Marangolo
M Marangolo
CTC Traversari
C Traversari
Lymphodepletion and infusion of autologous expanded tumour-infiltrating lymphocytes is effective therapy for patients with malignant melanoma. Antitumour responses are likely to be mediated by HLA class I- and II-restricted immune responses directed at tumour antigens. We assessed whether the peripheral blood of normal HLA-matched siblings of patients with melanoma could be used to generate lymphocytes with antimelanoma activity for adoptive immunotherapy after allogeneic blood or marrow transplantation. Melanoma cell lines were derived from two donors and were used to stimulate the mononuclear cells of three HLA-identical siblings. CD4+ clones dominated cultures. Of these, approximately half were directly cytotoxic towards recipient melanoma cells and secreted interferon-γ in response to tumour stimulation. More than half of the noncytotoxic clones also secreted interferon-γ after melanoma stimulation. No CD4+ clones responded to stimulation with recipient haemopoietic cells. The majority of CD8+ clones directly lysed recipient melanoma, but did not persist in long-term culture in vitro. No crossreactivity with recipient haemopoietic cells was observed. The antigenic target of one CD4+ clone was determined to be an HLA-DR11-restricted MAGE-3 epitope. Antigenic targets of the remaining clones were not elucidated, but appeared to be restricted through a non-HLA-DR class II molecule. We conclude that the blood of allogeneic HLA-matched sibling donors contains melanoma-reactive lymphocyte precursors directed at tumour-associated antigens. Adoptive immunotherapy with unselected or ex vivo-stimulated donor lymphocytes after allogeneic stem cell transplantation has a rational basis for the treatment of malignant melanoma.